nature research

Corresponding author(s): DBPR - COMMSMED-21-0167-T

Last updated by author(s): Jan 29, 2022

# Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

## Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

| n/a | Confirmed | |
|---|---|---|
| ☐ | ☒ | The exact sample size (*n*) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☒ | ☐ | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☐ | ☒ | The statistical test(s) used AND whether they are one- or two-sided<br>*Only common tests should be described solely by name; describe more complex techniques in the Methods section.* |
| ☒ | ☐ | A description of all covariates tested |
| ☒ | ☐ | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☐ | ☒ | For null hypothesis testing, the test statistic (e.g. *F*, *t*, *r*) with confidence intervals, effect sizes, degrees of freedom and *P* value noted<br>*Give P values as exact values whenever suitable.* |
| ☒ | ☐ | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☒ | ☐ | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☒ | ☐ | Estimates of effect sizes (e.g. Cohen's *d*, Pearson's *r*), indicating how they were calculated |

*Our web collection on statistics for biologists contains articles on many of the points above.*

## Software and code

Policy information about availability of computer code

| | |
|---|---|
| Data collection | Excel, GraphPad Prism |
| Data analysis | Excel, GraphPad Prism |

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Source data for the main figures are available as Supplementary Data 1. Additional data sets that support the findings of this study are available from the corresponding author upon reasonable request.

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| | |
|---|---|
| Sample size | Retrospective analysis, no sample size calculation |
| Data exclusions | No data were excluded |
| Replication | Not applicable in this retrospective analysis |
| Randomization | Retrospective analysis, no randomization |
| Blinding | Blinding was not applicable in this retrospective analysis |

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials & experimental systems

| n/a | Involved in the study |
|---|---|
| ☐ | ☐ Antibodies |
| ☐ | ☐ Eukaryotic cell lines |
| ☐ | ☐ Palaeontology and archaeology |
| ☐ | ☐ Animals and other organisms |
| ☐ | ☒ Human research participants |
| ☐ | ☒ Clinical data |
| ☐ | ☐ Dual use research of concern |

## Methods

| n/a | Involved in the study |
|---|---|
| ☐ | ☐ ChIP-seq |
| ☐ | ☐ Flow cytometry |
| ☐ | ☐ MRI-based neuroimaging |

## Antibodies

| | |
|---|---|
| Antibodies used | NA |
| Validation | NA |

## Eukaryotic cell lines

Policy information about cell lines

| | |
|---|---|
| Cell line source(s) | NA |
| Authentication | NA |
| Mycoplasma contamination | NA |
| Commonly misidentified lines (See ICLAC register) | NA |

## Palaeontology and Archaeology

| | |
|---|---|
| Specimen provenance | NA |
| Specimen deposition | NA |

| | |
|---|---|
| Dating methods | NA |

☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

| | |
|---|---|
| Ethics oversight | NA |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

| | |
|---|---|
| Laboratory animals | NA |
| Wild animals | NA |
| Field-collected samples | NA |
| Ethics oversight | NA |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Human research participants

Policy information about studies involving human research participants

| | |
|---|---|
| Population characteristics | NA |
| Recruitment | NA |
| Ethics oversight | Approval for QoL assessment was obtained from the Ethics committee of the University of Dresden, Germany on June 12 2017 (EK 255062017), University of Zurich, Switzerland on April 20th 2015 (KEK-ZHNo: 2014-0631).<br>The retrospective study on patients after pancreatectomy was approved by the TU Dresden Institutional Review Board (EK 310062019). |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about clinical studies

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

| | |
|---|---|
| Clinical trial registration | NA, retrospective analysis |
| Study protocol | NA, retrospective analysis |
| Data collection | Data were retrospectively collected from 2012 to 2018 in patients scheduled for pancreatic surgery at the Department of Visceral,-Thorax- and Vascular Surgery at the TU Dresden, Germany |
| Outcomes | NA |

## Dual use research of concern

Policy information about dual use research of concern

### Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

| No | Yes | |
|---|---|---|
| ☒ | ☐ | Public health |
| ☒ | ☐ | National security |
| ☒ | ☐ | Crops and/or livestock |
| ☒ | ☐ | Ecosystems |
| ☒ | ☐ | Any other significant area |

## Experiments of concern

Does the work involve any of these experiments of concern:

| No | Yes | |
|---|---|---|
| ☒ | ☐ | Demonstrate how to render a vaccine ineffective |
| ☒ | ☐ | Confer resistance to therapeutically useful antibiotics or antiviral agents |
| ☒ | ☐ | Enhance the virulence of a pathogen or render a nonpathogen virulent |
| ☒ | ☐ | Increase transmissibility of a pathogen |
| ☒ | ☐ | Alter the host range of a pathogen |
| ☒ | ☐ | Enable evasion of diagnostic/detection modalities |
| ☒ | ☐ | Enable the weaponization of a biological agent or toxin |
| ☒ | ☐ | Any other potentially harmful combination of experiments and agents |

# ChIP-seq

## Data deposition

☐ Confirm that both raw and final processed data have been deposited in a public database such as GEO.

☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

| | |
|---|---|
| Data access links<br>*May remain private before publication.* | NA |
| Files in database submission | NA |
| Genome browser session<br>(e.g. UCSC) | NA |

## Methodology

| | |
|---|---|
| Replicates | NA |
| Sequencing depth | NA |
| Antibodies | NA |
| Peak calling parameters | NA |
| Data quality | NA |
| Software | NA |

# Flow Cytometry

## Plots

Confirm that:

☐ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

☐ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

☐ All plots are contour plots with outliers or pseudocolor plots.

☐ A numerical value for number of cells or percentage (with statistics) is provided.

## Methodology

| | |
|---|---|
| Sample preparation | NA |
| Instrument | NA |
| Software | NA |
| Cell population abundance | NA |

Gating strategy NA

☐ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

Design type NA

Design specifications NA

Behavioral performance measures NA

### Acquisition

Imaging type(s) NA

Field strength NA

Sequence & imaging parameters NA

Area of acquisition NA

Diffusion MRI ☐ Used ☒ Not used

### Preprocessing

Preprocessing software NA

Normalization NA

Normalization template NA

Noise and artifact removal NA

Volume censoring NA

### Statistical modeling & inference

Model type and settings NA

Effect(s) tested NA

Specify type of analysis: ☐ Whole brain ☐ ROI-based ☐ Both

Statistic type for inference (See Eklund et al. 2016) NA

Correction NA

### Models & analysis

| n/a | Involved in the study |
|---|---|
| ☒ | ☐ Functional and/or effective connectivity |
| ☒ | ☐ Graph analysis |
| ☒ | ☐ Multivariate modeling or predictive analysis |